Congenital Myasthenic Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 24 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Longitudinal behavioral profiling reveals early-onset and persistent motor dysfunction in a VAChT-KD model for congenital myasthenic syndrome.
Barbosa Leticia A et al. — Behavioural brain research (2 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42468670/
- 2.
DOK7 Congenital Myasthenia Syndrome Presenting as an Isolated Complex Ophthalmoplegia.
Subasinghe Arachchige Thilan P et al. — Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/41995187/
- 3.
The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms.
Beeson David — Muscle & nerve (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42383519/
- 4.
AGRN-, LRP4-, MUSK-Related CMS: Clinical, Neurophysiological, Morphological, Genetic and Pathological Mechanisms.
Villar-Quiles Rocio-Nur et al. — Muscle & nerve (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42383531/
- 5.
Presynaptic Congenital Myasthenic Syndromes.
Maselli Ricardo A — Muscle & nerve (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42383533/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Congenital Myasthenic Syndrome
Congenital myasthenic syndrome is a group of rare inherited conditions in which signals do not pass properly from nerves to muscles. Symptoms usually begin in infancy or early childhood and include droopy eyelids, weak eye movements, feeding and breathing difficulties, and muscle weakness that worsens with activity. Medicines that improve nerve to muscle signalling help many people, but the right medicine depends on the genetic subtype.
Most Recent Research
The vesicular acetylcholine transporter knockdown (VAChT-KD) mouse is a genetic model of congenital myasthenic syndrome (CMS) characterized by impaired cholinergic transmission at the neuromuscular junction, resulting in presynaptic neuromuscular dysfunction. Here, we performed a longitudinal behavioral analysis to determine the onset and progression of motor deficits across development and adulthood, including potential sex-dependent effects. VAChT-KD mice exhibited early and persistent motor impairments. Neonatal animals showed reduced strength, impaired coordination, and delayed motor development compared to controls, and these deficits persisted into adulthood. Motor performance was consistently impaired in tests of global strength, while other behavioral measures revealed age- and sex-dependent differences. Notably, repeated exposure to motor tasks improved performance in mutant mice, indicating a learning component that partially compensates for underlying deficits. Across behavioral paradigms, genotype and age emerged as the primary determinants of motor performance. Importantly, the identification of early disease onset and measurable functional deficits across development highlights a critical window for therapeutic intervention. These findings support the use of VAChT-KD mice as a translational platform for testing early-stage therapies and underscore the importance of considering behavioral adaptation when designing preclinical studies for neuromuscular disorders.
Common Questions
What is Congenital Myasthenic Syndrome?
Congenital myasthenic syndrome is a group of rare inherited conditions in which signals do not pass properly from nerves to muscles. Symptoms usually begin in infancy or early childhood and include droopy eyelids, weak eye movements, feeding and breathing difficulties, and muscle weakness that worsens with activity. Medicines that improve nerve to muscle signalling help many people, but the right medicine depends on the genetic subtype.
How many clinical trials are available for Congenital Myasthenic Syndrome?
RareWays currently indexes 12 clinical trials for Congenital Myasthenic Syndrome, of which 4 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Congenital Myasthenic Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Congenital Myasthenic Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.